123 related articles for article (PubMed ID: 20810324)
1. Disease progression model for cognitive deterioration from Alzheimer's Disease Neuroimaging Initiative database.
Ito K; Corrigan B; Zhao Q; French J; Miller R; Soares H; Katz E; Nicholas T; Billing B; Anziano R; Fullerton T;
Alzheimers Dement; 2011 Mar; 7(2):151-60. PubMed ID: 20810324
[TBL] [Abstract][Full Text] [Related]
2. Modeling Alzheimer's disease progression using the disease system analysis approach.
Gomeni R; Simeoni M; Zvartau-Hind M; Irizarry MC; Austin D; Gold M
Alzheimers Dement; 2012 Jan; 8(1):39-50. PubMed ID: 21782528
[TBL] [Abstract][Full Text] [Related]
3. Clinical trials in Alzheimer's disease. Calculating Alzheimer's Disease Assessment Scale-cognitive subsection with the data from the consortium to establish a registry for Alzheimer's disease.
Gillen TE; Gregg KM; Yuan H; Kurth MC; Krishnan KR
Psychopharmacol Bull; 2001; 35(2):83-96. PubMed ID: 12397889
[TBL] [Abstract][Full Text] [Related]
4. An improved model for disease progression in patients from the Alzheimer's disease neuroimaging initiative.
Samtani MN; Farnum M; Lobanov V; Yang E; Raghavan N; Dibernardo A; Narayan V;
J Clin Pharmacol; 2012 May; 52(5):629-44. PubMed ID: 21659625
[TBL] [Abstract][Full Text] [Related]
5. Can CSF biomarkers or pre-treatment progression rate predict response to cholinesterase inhibitor treatment in Alzheimer's disease?
Wallin AK; Hansson O; Blennow K; Londos E; Minthon L
Int J Geriatr Psychiatry; 2009 Jun; 24(6):638-47. PubMed ID: 19123199
[TBL] [Abstract][Full Text] [Related]
6. Japanese Alzheimer's Disease Neuroimaging Initiative: present status and future.
Iwatsubo T
Alzheimers Dement; 2010 May; 6(3):297-9. PubMed ID: 20451880
[TBL] [Abstract][Full Text] [Related]
7. The validity and reliability of the Turkish version of Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) in patients with mild and moderate Alzheimer's disease and normal subjects.
Mavioglu H; Gedizlioglu M; Akyel S; Aslaner T; Eser E
Int J Geriatr Psychiatry; 2006 Mar; 21(3):259-65. PubMed ID: 16477580
[TBL] [Abstract][Full Text] [Related]
8. The Alzheimer's Disease Assessment Scale-Cognitive subscale: normative data for older adult controls.
Graham DP; Cully JA; Snow AL; Massman P; Doody R
Alzheimer Dis Assoc Disord; 2004; 18(4):236-40. PubMed ID: 15592137
[TBL] [Abstract][Full Text] [Related]
9. A study of the Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog) in an Icelandic elderly population.
Hannesdóttir K; Snaedal J
Nord J Psychiatry; 2002; 56(3):201-6. PubMed ID: 12079572
[TBL] [Abstract][Full Text] [Related]
10. Interaction between Apolipoprotein epsilon 4 and traumatic brain injury in patients with Alzheimer's disease and Mild Cognitive Impairment.
Mauri M; Sinforiani E; Bono G; Cittadella R; Quattrone A; Boller F; Nappi G
Funct Neurol; 2006; 21(4):223-8. PubMed ID: 17367583
[TBL] [Abstract][Full Text] [Related]
11. A longitudinal study of Alzheimer's disease: rates of cognitive and functional decline.
Suh GH; Ju YS; Yeon BK; Shah A
Int J Geriatr Psychiatry; 2004 Sep; 19(9):817-24. PubMed ID: 15352138
[TBL] [Abstract][Full Text] [Related]
12. The apolipoprotein E epsilon4 allele and incident Alzheimer's disease in persons with mild cognitive impairment.
Aggarwal NT; Wilson RS; Beck TL; Bienias JL; Berry-Kravis E; Bennett DA
Neurocase; 2005 Feb; 11(1):3-7. PubMed ID: 15804918
[TBL] [Abstract][Full Text] [Related]
13. Potential long-term effects of rivastigmine on disease progression may be linked to drug effects on vascular changes in Alzheimer brains.
Erkinjuntti T; Skoog I; Lane R; Andrews C
Int J Clin Pract; 2003 Nov; 57(9):756-60. PubMed ID: 14686563
[TBL] [Abstract][Full Text] [Related]
14. Asymptomatic spontaneous cerebral emboli predict cognitive and functional decline in dementia.
Purandare N; Voshaar RC; Morris J; Byrne JE; Wren J; Heller RF; McCollum CN; Burns A
Biol Psychiatry; 2007 Aug; 62(4):339-44. PubMed ID: 17531959
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of 6-month decline in ADAS-cog for survival without severe Alzheimer's disease.
Helmer C; Andrieu S; Pérès K; Orgogozo JM; Vellas B; Dartigues JF;
Dement Geriatr Cogn Disord; 2007; 23(3):168-74. PubMed ID: 17215578
[TBL] [Abstract][Full Text] [Related]
16. Clinical effects of high oral dose of donepezil for patients with Alzheimer's disease in Japan.
Nozawa M; Ichimiya Y; Nozawa E; Utumi Y; Sugiyama H; Murayama N; Iseki E; Arai H
Psychogeriatrics; 2009 Jun; 9(2):50-5. PubMed ID: 19604325
[TBL] [Abstract][Full Text] [Related]
17. Evolution of blood pressure in patients with Alzheimer's disease: a one year survey of a French Cohort (REAL.FR).
Hanon O; Latour F; Seux ML; Lenoir H; Forette F; Rigaud AS;
J Nutr Health Aging; 2005; 9(2):106-11. PubMed ID: 15791354
[TBL] [Abstract][Full Text] [Related]
18. How well do the ADAS-cog and its subscales measure cognitive dysfunction in Alzheimer's disease?
Benge JF; Balsis S; Geraci L; Massman PJ; Doody RS
Dement Geriatr Cogn Disord; 2009; 28(1):63-9. PubMed ID: 19641319
[TBL] [Abstract][Full Text] [Related]
19. [Presentation and stability of cognitive and noncognitive symptom patterns in patients with Alzheimer's disease. Disease course over a two-year period under constant treatment conditions with rivastigmine].
Wobrock T; Retz-Junginger P; Retz W; Supprian T; Rösler M
Fortschr Neurol Psychiatr; 2003 Apr; 71(4):199-204. PubMed ID: 12677553
[TBL] [Abstract][Full Text] [Related]
20. Patterns of decline and evidence of subgroups in patients with Alzheimer's disease taking galantamine for up to 48 months.
Rockwood K; Dai D; Mitnitski A
Int J Geriatr Psychiatry; 2008 Feb; 23(2):207-14. PubMed ID: 17621382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
